/Eli%20Lilly%20and%20Co_%20by%20Sergio%20Photone%20via%20Shutterstock.jpg)
Eli Lilly (LLY) shares are extending gains on Wednesday after the FDA approved Foundayo — the company’s first once-daily oral GLP-1 for chronic weight management. As investors cheered the pivot to a more convenient, non-injectable alternative for obesity treatment, LLY broke above its 20-day moving average (MA), indicating the upward momentum may sustain in the near-term.
Despite the headline rally, however, Eli Lilly stock remains down over 10% versus the start of 2026.